

Form PTO-1449 (modified)		Atty. Docket No.: ARCD:389US	Serial No.: 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Mark J. RATAIN <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1634
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C222	"Prosecution history for 90/007,601," Reexamination of United States Patent Number 6,395,481
	C223	Cote <i>et al.</i> , "UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan," <i>Clin. Cancer Res.</i> , 13(11):3269-3275, 2007.
	C224	Falandry <i>et al.</i> , "Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial," <i>J. Clin. Oncology</i> , 2007 ASCO Annual Meeting Proceedings Part 1, 25(18S):2510, 2007.
	C225	Innocenti <i>et al.</i> , "A genotype-directed phase I study of irinotecan in advanced cancer patients," <i>J. Clin. Oncology</i> , 2007 ASCO Annual Meeting Proceedings Part 1, 25(18S):2502, 2007.
	C226	Iyer <i>et al.</i> , "Glucuronidation of TAS-103: A Novel Anticancer Agent," <i>Proc. Am. Soc. Clin. Oncol.</i> , 17:187a, No. 722, 1998.
	C227	Owens and Ritter, "The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes," <i>Pharmacogenetics</i> , 2:93-108, 1992.
	C228	Takahashi <i>et al.</i> , "The Role of Glucuronidation in 7-Ethyl-10-hydroxycamptothecin Resistance in vitro," <i>Jpn. J. Cancer Res.</i> , 88:1211-1217, 1997.
	C229	Utsugi <i>et al.</i> , "Antitumor Activity of a Novel Quinoline Derivative, TAS-103, with Inhibitory Effects on Topoisomerases I and II," <i>Jpn. J. Cancer Res.</i> , 88:992-1002, 1997.

25797494.1

EXAMINER: /Sarae Bausch/

DATE CONSIDERED: 08/12/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.